Introduction {#sec1}
============

As a new class of functional non-coding RNAs (ncRNAs), long ncRNAs (lncRNAs) are made up of over 200 nts and lack the ability of protein coding \[[@B1]\]. Recently, the association between lncRNA and human diseases, especially cancer, has been widely investigated. Compared with other ncRNAs, lncRNAs play an important role in numerous vital activities of cell, including the regulation of epigenetic modifications, cell cycle, cell differentiation, and stress response \[[@B2]\]. The most important function of lncRNA is involvement in the tumorigenesis as proto-oncogene \[[@B3]\] or anti-oncogene \[[@B4]\]. Moreover, the differential expression of lncRNA may facilitate tumor cell proliferation, invasion, and metastasis \[[@B5]\].

Currently, single nucleotide polymorphisms (SNPs) are the most common genetic variants of concern and universally present in lncRNA genes. It is predicted that the expression and function of lncRNAs are affected by SNPs \[[@B6]\]. Studies have also suggested that polymorphism in lncRNA may influence the process of splicing and stability of mRNA conformation, leading to the modification of their interacting partners \[[@B7]\]. To date, several studies have assessed the associations amongst more than 20 lncRNA polymorphisms and susceptibility of cancers, but the results are inconsistent.

In the present study, we conducted a meta-analysis of epidemiological studies to explore the associations between five lncRNA SNPs and overall cancer risk. Furthermore, our study may shed some light on the biomarkers for predicting cancer risk.

Materials and methods {#sec2}
=====================

Publication search {#sec2-1}
------------------

A computerized literature search was performed in the Medline, PubMed, Web of Science, and Embase database up to 6 Februrary 2018. The search strategy included the terms ('lncRNA' or 'long non-coding RNA') and ('polymorphisms' or 'variants' or 'variation' or 'SNP') and ('cancer' or 'carcinoma' or 'tumor' or 'neoplasm'). To be eligible for inclusion in the meta-analysis, a study must meet the following criteria: (i) case--control study or cohort study; (ii) assessing the association between lncRNA SNPs and cancer risk; (iii) having an available genotype or allele frequency for estimating an odds ratio (OR) with 95% confidence interval (95% CI) or hazard ratio (HR) with 95% CI; and (iv) genotype frequencies in controls being consistent with those expected from Hardy--Weinberg equilibrium (HWE) (*P*\>0.05). The exclusion criteria were: (i) duplicate studies; (ii) not relevant to cancer or lncRNA SNPs; or (iii) no available data and the authors could not be contacted.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Two investigators (X.H. and W.Z.) evaluated the eligibility of all retrieved studies and extracted the relevant data independently. Extracted databases were then cross-checked between the two authors to rule out any discrepancy. Disagreement was resolved by consulting with the third investigator (Z.S.). The study quality was assessed in accordance with the Newcastle--Ottawa Scale (NOS) (Supplementary Table S1). Eight items were extracted, and each item scored 1. The total scores ranged from 0 to 8. If the scores were ≥7, then the study was considered to be of high quality.

Statistical analysis {#sec2-3}
--------------------

The statistical analysis was performed using STATA 14. Estimates were summarized as ORs with 95% CIs for each study (*P*\<0.05 was considered statistically significant). The genotype frequencies of the lncRNA polymorphisms for the HWE were calculated for the controls using the chi-square test, and *P*\<0.05 was considered as significant disequilibrium. The between-study heterogeneity was evaluated by using the chi-square test and the *I^2^* statistic. An *I^2^* value of \>50% of the *I^2^* statistic was considered to indicate significant heterogeneity \[[@B8]\]. When a significant heterogeneity existed across the included studies, a random-effects model was used for the analysis. Otherwise, the fixed-effects model was used. Subgroup analyses were performed to detect the source of heterogeneity. As to genotype comparison, the risks of the heterozygote and variant homozygote compared with the wild-type homozygote were estimated respectively. Then we evaluated the dominant and recessive effects of the variant allele (heterozygote + variant homozygote compared with wild-type homozygote and variant homozygote compared with heterozygote + wild-type homozygote), respectively. Begg's rank correlation and Egger's linear regression method were used to assess the publication bias statistically. A two-tailed *P*-value \<0.05 implies a statistically significant publication bias \[[@B9],[@B10]\]. We further conducted sensitivity analyses to substantiate the stability of results and detect the potential source of heterogeneity.

Results {#sec3}
=======

Characteristics of the eligible studies {#sec3-1}
---------------------------------------

Finally, a total of 234 articles were included in the meta-analysis, 42 case--control studies that met our inclusion criteria were included in quantitative synthesis, and 17 of them involving 9548 cases and 9828 controls were included in our meta-analysis ([Figure 1](#F1){ref-type="fig"}). [Table 1](#T1){ref-type="table"} lists the characteristics of the eligible studies. Amongst the 17 case--control studies, the control groups of 9 were hospital-based and 8 were population-based. Genotyping methods included tetra-primer amplification refractory mutation system (T-ARMS)-PCR (2), MALDI-TOF MS (1), PCR-restriction fragment length polymorphism (RFLP) (5), created restriction site (CRS)-RFLP (1), TaqMan (3), MassARRAY (4), multiplex PCR-based Invader assay (1), and SNPlex Genotyping System (1) ([Table 1](#T1){ref-type="table"}). [Table 2](#T2){ref-type="table"} presents the genotype frequency distributions of a total 19 SNPs in five lncRNA genes (antisense ncRNA in the INK4 locus (*ANRIL*), metastasis-associated lung adenocarcinoma transcript 1 (*MALAT1*), HOXA distal transcript antisense RNA (*HOTTIP*), highly up-regulated in liver cancer (*HULC*), and prostate cancer-associated ncRNA 1 (*PRNCR1*)) involved in the 17 eligible studies. After removal of those records for which *P*~HWE~\<0.05, seven SNPs were found to be only based on one single eligible study. They were ANRIL rs2151280, MALAT1 rs3200401, MALAT1 rs7927113, MALAT1 rs1194338, HOTTIP rs5883064, PRNCR1 rs7841060, and PRNCR1 rs7463708. Therefore, the remaining 12 lncRNA SNPs were included in our final calculation ([Table 2](#T2){ref-type="table"}).

![The studies identified in this meta-analysis based on the inclusion and exclusion criteria](bsr-38-bsr20180365-g1){#F1}

###### Characteristics of eligible studies

  Number   First author         Year   Country   Ethnicity   Sample size   Source of control groups   Genotyping method   Adjusted factors              Citation                                                                          
  -------- -------------------- ------ --------- ----------- ------------- -------------------------- ------------------- ----------------------------- --------------------------------------------------------------------------------- ------------
  1        Khorshidi et al.     2017   Iran      Asian       122           200                        PB                  T-ARMS-PCR                    Age                                                                               \[[@B11]\]
  2        Kang et al.          2015   China     Asian       380           380                        HB                  MALDI-TOF MS                  Age, sex, and drinking status                                                     \[[@B12]\]
  3        Taheri et al.        2017   Iran      Asian       125           220                        PB                  T-ARMS-PCR                    Age, BMI, and smoking history                                                     \[[@B13]\]
  4        Peng et al.          2017   China     Asian       487           489                        PB                  PCR-RFLP, CRS-RFLP            Age                                                                               \[[@B14]\]
  5        Liu et al.           2012   China     Asian       1300          1344                       PB                  TaqMan Assay-PCR              Age, sex, smoking rate, and HBV chronic infection                                 \[[@B15]\]
  6        Li et al.            2017   China     Asian       821           857                        HB                  MassARRAY                     Age, sex, BMI, smoking, and alcohol drinking                                      \[[@B16]\]
  7        Gong et al.          2016   China     Asian       498           213                        HB                  MassARRAY                     Age and sex                                                                       \[[@B17]\]
  8        Hu et al.            2017   China     Asian       921           921                        PB                  TaqMan Assay-PCR              Age, sex, and area of residence                                                   \[[@B18]\]
  9        Shaker et al.        2017   Egypt     Caucasian   120           96                         PB                  TaqMan Assay-PCR              Age and sex                                                                       \[[@B19]\]
  10       He et al.            2017   China     Asian       494           494                        HB                  MassARRAY                     *Helicobacter pylori* infection rate, age, sex, and smoking and drinking status   \[[@B20]\]
  11       Duan et al.          2017   China     Asian       470           470                        HB                  PCR-RFLP                      Age, sex, and drinking                                                            \[[@B6]\]
  12       Li et al.            2016   China     Asian       219           394                        HB                  PCR-RFLP                      Age and sex                                                                       \[[@B21]\]
  13       Sattarifard et al.   2017   Iran      Asian       178           180                        HB                  PCR-RFLP                      Age                                                                               \[[@B22]\]
  14       Li et al.            2013   China     Asian       313           595                        HB                  PCR-RFLP                      Age and sex                                                                       \[[@B23]\]
  15       Chung et al.         2010   Japan     Asian       1504          1554                       HB                  Multiplex PCR-based Invader   NM                                                                                \[[@B24]\]
  16       Salinas et al.       2008   U.S.A.    Caucasian   1308          1266                       PB                  SNPlex genotyping system      Age                                                                               \[[@B25]\]
  17       Zheng et al.         2010   China     Asian       288           155                        PB                  MassARRAY                     Age, sex, and BMI                                                                 \[[@B26]\]

Abbreviations: BMI, body mass index; HB, hospital based; NM, not mentioned; PB, population based.

###### Genotype frequency distributions of lncRNA SNPs studied in included studies

  First author         Year   lncRNA   SNPs                                                 Type of cancer      Sample size   Case   Control   *P* for HWE   Quality score                                                                 
  -------------------- ------ -------- ---------------------------------------------------- ------------------- ------------- ------ --------- ------------- --------------- ------ ----- ----- ------------------------------------------ ---
  Khorshidi et al.     2017   ANRIL    rs1333045 (C/T)                                      Breast cancer       122           200    31        52            39              57     100   43    0.944                                      7
                              ANRIL    rs1333048 (A/C)                                      Breast cancer       122           200    39        51            32              51     97    52    0.672                                      
                              ANRIL    rs4977574 (A/G)                                      Breast cancer       122           200    61        44            17              81     93    26    0.931                                      
                              ANRIL    rs10757278 (A/G)                                     Breast cancer       122           200    38        62            22              74     100   26    0.387                                      
  Kang et al.          2015   ANRIL    rs2151280 (C/T)[^1^](#T2TFN1){ref-type="table-fn"}   ESCC                380           380    57        153           161             43     173   154   0.595                                      8
  Taheri et al.        2017   ANRIL    rs1333045 (C/T)                                      Prostate cancer     125           220    41        61            23              75     102   43    0.435                                      7
                              ANRIL    rs1333048 (A/C)                                      Prostate cancer     148           220    25        65            58              101    88    31    0.103                                      
                              ANRIL    rs4977574 (A/G)                                      Prostate cancer     114           220    55        46            13              79     109   32    0.570                                      
                              ANRIL    rs10757278 (A/G)                                     Prostate cancer     132           220    14        65            53              95     93    32    0.241                                      
  Peng et al.          2017   MALAT1   rs3200401 (T/C)[^1^](#T2TFN1){ref-type="table-fn"}   Breast cancer       487           489    357       120           10              338    145   6     0.057                                      8
                              MALAT1   rs619586 (A/G)                                       Breast cancer       487           489    415       65            7               386    93    10    0.124                                      
                              MALAT1   rs7927113 (A/G)[^1^](#T2TFN1){ref-type="table-fn"}   Breast cancer       487           489    476       10            1               469    19    1     0.096                                      
  Liu et al.           2012   MALAT1   rs619586 (A/G)                                       HCC                 1300          1344   1094      169           5               1115   205   10    0.864                                      8
  Li et al.            2017   MALAT1   rs1194338 (A/C)[^1^](#T2TFN1){ref-type="table-fn"}   CRC                 821           857    389       357           72              381    377   95    0.905                                      8
  Gong et al.          2016   HOTTIP   rs5883064 (C/T)[^1^](#T2TFN1){ref-type="table-fn"}   Lung cancer         491           206    161       252           78              89     87    30    0.252                                      8
                              HOTTIP   rs1859168 (A/C)                                      Lung cancer         491           210    151       254           86              85     94    31    0.549                                      
  Hu et al.            2017   HOTTIP   rs1859168 (A/C)                                      Pancreatic cancer   921           921    239       497           185             364    421   136   0.428                                      8
  Duan et al.          2017   HOTTIP   rs1859168 (A/C)                                      Gastric cancer      455           451    141       117           191             102    210   139   0.185                                      8
  Kang et al.          2015   HULC     rs7763881 (A/C)                                      ESCC                380           380    122       168           84              99     195   81    0.412                                      8
  Shaker et al.        2017   HULC     rs7763881 (A/C)                                      CRC                 120           96     32        88            0               12     84    0     0.000[^2^](#T2TFN2){ref-type="table-fn"}   6
  Liu et al.           2012   HULC     rs7763881 (A/C)                                      HCC                 1300          1344   377       617           283             333    695   288   0.057                                      8
  He et al.            2017   PRNCR1   rs16901946 (A/G)                                     Gastric cancer      494           494    261       203           30              301    176   17    0.153                                      8
                              PRNCR1   rs13252298 (A/G)                                     Gastric cancer      494           494    236       215           43              209    235   50    0.173                                      
                              PRNCR1   rs7463708 (G/T)[^1^](#T2TFN1){ref-type="table-fn"}   Gastric cancer      494           494    241       209           44              228    209   57    0.390                                      
                              PRNCR1   rs7007694 (C/T)                                      Gastric cancer      494           494    264       199           31              272    198   24    0.111                                      
  Li et al.            2016   PRNCR1   rs16901946 (A/G)                                     Gastric cancer      219           394    125       92            2               230    135   29    0.144                                      8
                              PRNCR1   rs13252298 (A/G)                                     Gastric cancer      219           394    88        107           24              198    161   35    0.781                                      
                              PRNCR1   rs7007694 (C/T)                                      Gastric cancer      219           394    142       72            5               214    159   21    0.219                                      
                              PRNCR1   rs1016343 (C/T)                                      Gastric cancer      219           394    78        109           32              140    176   78    0.096                                      
                              PRNCR1   rs1456315 (A/G)                                      Gastric cancer      219           394    109       103           7               179    177   38    0.546                                      
  Sattarifard et al.   2017   PRNCR1   rs13252298 (A/G)                                     Prostate cancer     178           179    33        107           38              25     141   13    0.000[^2^](#T2TFN2){ref-type="table-fn"}   7
                              PRNCR1   rs1456315 (A/G)                                      Prostate cancer     178           180    30        148           0               92     88    0     0.000[^2^](#T2TFN2){ref-type="table-fn"}   
                              PRNCR1   rs7007694 (C/T)                                      Prostate cancer     178           180    150       28            0               139    41    0     0.085                                      
                              PRNCR1   rs7841060 (G/T)[^1^](#T2TFN1){ref-type="table-fn"}   Prostate cancer     178           180    29        149           0               96     84    0     0.000[^2^](#T2TFN2){ref-type="table-fn"}   
  Li et al.            2013   PRNCR1   rs1016343 (C/T)                                      CRC                 313           595    117       156           40              227    276   92    0.593                                      8
                              PRNCR1   rs13252298 (A/G)                                     CRC                 313           595    166       121           26              264    270   61    0.508                                      
                              PRNCR1   rs16901946 (A/G)                                     CRC                 313           595    175       117           138             338    232   257   0.000[^2^](#T2TFN2){ref-type="table-fn"}   
                              PRNCR1   rs1456315 (A/G)                                      CRC                 313           595    167       119           27              294    262   39    0.055                                      
                              PRNCR1   rs7007694 (C/T)                                      CRC                 313           595    184       107           22              362    208   25    0.474                                      
  Chung et al.         2010   PRNCR1   rs1016343 (C/T)                                      Prostate cancer     1504          1554   650       667           185             841    608   103   0.624                                      7
                              PRNCR1   rs13252298 (A/G)                                     Prostate cancer     1504          1554   808       556           137             609    737   204   0.416                                      
                              PRNCR1   rs16901946 (A/G)                                     Prostate cancer     1504          1554   690       637           177             783    645   126   0.671                                      
                              PRNCR1   rs1456315 (A/G)                                      Prostate cancer     1504          1554   905       495           104             663    703   187   0.975                                      
                              PRNCR1   rs7007694 (C/T)                                      Prostate cancer     1504          1554   656       650           191             700    684   170   0.880                                      
  Salinas et al.       2008   PRNCR1   rs1456315 (A/G)                                      Prostate cancer     1308          1266   464       598           192             401    605   227   0.964                                      7
                              PRNCR1   rs1016343 (C/T)                                      Prostate cancer     1253          1233   711       454           88              796    385   52    0.529                                      
  Zheng et al.         2010   PRNCR1   rs1016343 (C/T)                                      Prostate cancer     284           147    76        159           49              66     65    16    0.999                                      7

Abbreviations: CRC, colorectal cancer; EOC, epithelial ovarian cancer; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma.

Not included due to the limited number of studies for this lncRNA locus.

Not included because the *P* of the HWE was \<0.05.

Quantitative data synthesis of 12 SNPs in five highly studied lncRNA genes {#sec3-2}
--------------------------------------------------------------------------

### Four SNPs in ANRIL {#sec3-2-1}

First, we calculated the pooled ORs of all eligible studies to estimate the association between the four SNPs in ANRIL and overall cancer risk. The rs1333045 C/T polymorphism was not associated with cancer; and the rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G polymorphisms were associated with overall cancer risk. The rs1333048 A/C polymorphism was associated with increased overall risk of cancer in all genetic models (C compared with A: *P*=0.000, OR = 2.06, 95% CI = 1.64--2.57; CC compared with AA: *P*=0.000, OR = 4.26, 95% CI = 2.67--6.78; AC compared with AA: *P*=0.049, OR = 1.45, 95% CI = 1.00--2.10; dominant model: *P*=0.001, OR = 1.80, 95% CI = 1.28--2.51; recessive model: *P*=0.000, OR = 2.01, 95% CI = 1.42--2.84). For the rs4977574 A/G polymorphism, both the heterozygote type AG and the dominant model were associated with decreased overall risk of cancer compared with the wild-type AA (AG compared with AA: *P*=0.006, OR = 0.62, 95% CI = 0.44--0.87; dominant model: *P*=0.007, OR = 0.64, 95% CI = 0.46--0.88). However, both the mutation type GG and the allelic model were associated with increased overall risk of cancer (GG compared with AA: *P*=0.000, OR = 2.40, 95% CI = 1.60--3.59; G compared with A: *P*=0.000, OR = 1.68, 95% CI = 1.35--2.08). For the rs10757278 A/G polymorphism, the heterozygote type AG, the dominant model, and the recessive model were associated with increased overall risk of cancer (AG compared with AA: *P*=0.000, OR = 2.13, 95% CI = 1.45--3.12; dominant model: *P*=0.000, OR = 2.58, 95% CI = 1.80--3.69; recessive model: *P*=0.000, OR = 2.64, 95% CI = 1.79--3.88). Nevertheless, the allelic model was associated with decreased overall risk of cancer (G compared with A: *P*=0.030, OR = 0.77, 95% CI = 0.60--0.97, [Table 3](#T3){ref-type="table"}).

###### Meta-analysis of the association between common SNPs and cancer risk

  Stratification       *n*   Allelic model            Mutation homozygote compared with wild-type        Heterozygote compared with wild-type   Dominant model           Recessive model                                                                                                                                                                                                                                                                                                     
  -------------------- ----- ------------------------ -------------------------------------------------- -------------------------------------- ------------------------ -------------------------------------------------- ---------- ------------------------ -------------------------------------------------- ---------- ------------------------ ---------------------------------------------- ---------- ------------------------ -------------------------------------------------- ----------
  **ANRIL**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  rs1333048 (A/C)      2     **2.06 (1.64-- 2.57)**   **0.000**[**^1^**](#T3TFN1){ref-type="table-fn"}   **94.3**                               **4.26 (2.67-- 6.78)**   **0.000**[**^1^**](#T3TFN1){ref-type="table-fn"}   **93.1**   **1.45 (1.00-- 2.10)**   **0.049**[**^1^**](#T3TFN1){ref-type="table-fn"}   **93.0**   **1.80 (1.28-- 2.51)**   **0.001**[^1^](#T3TFN1){ref-type="table-fn"}   **95.7**   **2.01 (1.42-- 2.84)**   **0.000**[^a^](#T3TFN1){ref-type="table-fn"}       **92.7**
  rs4977574 (A/G)      2     **1.68 (1.35-- 2.08)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **96.7**                               **2.40 (1.60-- 3.59)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **96.1**   **0.62 (0.44-- 0.87)**   **0.006**                                          **0.0**    **0.64 (0.46-- 0.88)**   **0.007**                                      **0.0**    0.91 (0.57-- 1.46)       0.693                                              0.0
  rs10757278 (A/G)     2     **0.77 (0.60-- 0.97)**   **0.030**                                          **0.0**                                0.72 (0.43-- 1.18)       0.192                                              0.0        **2.13 (1.45-- 3.12)**   **0.000**[**^1^**](#T3TFN1){ref-type="table-fn"}   **90.7**   **2.58 (1.80-- 3.69)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **93.9**   **2.64 (1.79-- 3.88)**   **0.000**[**^1^**](#T3TFN1){ref-type="table-fn"}   **82.7**
  rs1333045 (C/T)      2     1.15 (0.92-- 1.43)       0.236                                              27.7                                   1.29 (0.83-- 1.99)       0.260                                              28.5       1.03 (0.71-- 1.48)       0.874                                              0.0        1.11 (0.79-- 1.56)       0.556                                          0.0        1.30 (0.89-- 1.88)       0.175[^1^](#T3TFN1){ref-type="table-fn"}           60.4
  **MALAT1**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  rs619586 (A/G)       2     **0.77 (0.65-- 0.92)**   **0.003**                                          **9.7**                                0.58 (0.28-- 1.20)       0.141                                              0.0        **0.78 (0.65-- 0.94)**   **0.009**                                          **33.5**   **0.77 (0.64-- 0.92)**   **0.004**[^1^](#T3TFN1){ref-type="table-fn"}   **27.9**   0.61 (0.30-- 1.26)       0.180                                              0.0
  **HOTTIP**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  rs1859168 (A/C)      3     **1.32 (1.19-- 1.45)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **75.2**                               **1.54 (1.27-- 1.87)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **81.8**   **1.24 (1.06-- 1.45)**   **0.006**[^1^](#T3TFN1){ref-type="table-fn"}       **96.4**   **1.37 (1.19-- 1.59)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **94.3**   **1.49 (1.26-- 1.76)**   **0.000**                                          **0.0**
  **HULC**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  rs7763881 (A/C)      3     **0.91 (0.83-- 0.99)**   **0.040**                                          **0.0**                                0.86 (0.71-- 1.05)       0.132                                              0.0        **0.74 (0.63-- 0.86)**   **0.000**                                          **41.3**   **0.77 (0.66-- 0.89)**   **0.000**                                      **45.2**   1.02 (0.87-- 1.21)       0.776                                              0.0
  **PRNCR1**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  rs16901946 (G/A)     3     **1.15 (1.06-- 1.25)**   **0.001**[^1^](#T3TFN1){ref-type="table-fn"}       **66.4**                               **1.26 (1.06--1.50)**    **0.008**[^1^](#T3TFN1){ref-type="table-fn"}       **82.6**   **1.15 (1.03-- 1.28)**   **0.017**                                          **0.0**    **1.17 (1.06-- 1.30)**   **0.003**                                      **21.6**   **1.21 (1.03--1.43)**    **0.019**[^1^](#T3TFN1){ref-type="table-fn"}       **81.7**
  Type of cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Gastric cancer       2     1.15 (0.97-- 1.35)       0.104[^1^](#T3TFN1){ref-type="table-fn"}           83.8                                   0.96 (0.59-- 1.56)       0.871[^1^](#T3TFN1){ref-type="table-fn"}           92.4       **1.30 (1.06-- 1.60)**   **0.013**                                          **0.0**    **1.26 (1.03-- 1.54)**   **0.025**                                      **40.7**   0.86 (0.53-- 1.39)       0.533[^1^](#T3TFN1){ref-type="table-fn"}           92.4
  rs13252298 (G/A)     4     **0.78 (0.72-- 0.85)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **89.2**                               **0.68 (0.56-- 0.81)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **81.6**   **0.69 (0.62-- 0.77)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **85.1**   **0.81 (0.73-- 0.90)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **73.7**   0.85 (0.72-- 1.01)       0.065[^1^](#T3TFN1){ref-type="table-fn"}           82.7
  **Type of cancer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Gastric cancer       2     1.00 (0.86-- 1.16)       0.994[^1^](#T3TFN1){ref-type="table-fn"}           86.6                                   0.99 (0.69-- 1.41)       0.945[^1^](#T3TFN1){ref-type="table-fn"}           72.1       1.01 (0.82-- 1.25)       0.923[^1^](#T3TFN1){ref-type="table-fn"}           86.7       1.01 (0.83-- 1.23)       0.945[^1^](#T3TFN1){ref-type="table-fn"}       88.5       0.98 (0.70-- 1.38)       0.921                                              21.1
  rs7007694 (C/T)      5     1.03 (0.95-- 1.12)       0.522[^1^](#T3TFN1){ref-type="table-fn"}           69.0                                   1.19 (0.98-- 1.45)       0.086[^1^](#T3TFN1){ref-type="table-fn"}           58.4       0.96 (0.86-- 1.07)       0.443                                              42.5       0.99 (0.89-- 1.10)       0.848[^1^](#T3TFN1){ref-type="table-fn"}       61.0       1.19 (0.98-- 1.44)       0.070                                              49.9
  **Type of cancer**                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Gastric cancer       2     0.92 (0.78-- 1.09)       0.332[^1^](#T3TFN1){ref-type="table-fn"}           85.8                                   0.92 (0.58-- 1.47)       0.730[^1^](#T3TFN1){ref-type="table-fn"}           80.4       0.89 (0.73-- 1.10)       0.280[^1^](#T3TFN1){ref-type="table-fn"}           71.6       0.89 (0.73-- 1.09)       0.269[^1^](#T3TFN1){ref-type="table-fn"}       81.7       0.96 (0.60-- 1.52)       0.853[^1^](#T3TFN1){ref-type="table-fn"}           75.0
  Prostate cancer      2     1.05 (0.95-- 1.16)       0.371[^1^](#T3TFN1){ref-type="table-fn"}           69.6                                   1.20 (0.95-- 1.51)       0.126                                                         0.98 (0.85-- 1.13)       0.769[^1^](#T3TFN1){ref-type="table-fn"}           64.0       1.02 (0.88-- 1.16)       0.832[^1^](#T3TFN1){ref-type="table-fn"}       69.2       1.19 (0.96-- 1.48)       0.120                                              
  rs1016343 (T/C)      5     **1.31 (1.22-- 1.41)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **85.2**                               **1.67 (1.41-- 1.97)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **86.0**   **1.35 (1.22-- 1.49)**   **0.000**                                          **47.2**   **1.41 (1.28-- 1.55)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **73.1**   **1.42 (1.21-- 1.66)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **84.5**
  **Ethnicity**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Asian                4     **1.30 (1.19-- 1.41)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **88.7**                               **1.60 (1.33-- 1.94)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **89.3**   **1.37 (1.21-- 1.54)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **59.8**   **1.42 (1.26-- 1.59)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **79.8**   **1.35 (1.13-- 1.61)**   **0.001**[^1^](#T3TFN1){ref-type="table-fn"}       **87.7**
  Type of cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Prostate cancer      3     **1.45 (1.34-- 1.57)**   **0.000**                                          **1.9**                                **2.21 (1.81-- 2.70)**   **0.000**                                          **0.0**    **1.41 (1.27-- 1.57)**   **0.000**                                          **49.3**   **1.51 (1.37-- 1.68)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **55.6**   **1.86 (1.54-- 2.26)**   **0.000**                                          **0.0**
  rs1456315 (G/A)      4     **0.77 (0.72-- 0.83)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **94.6**                               **0.59 (0.49-- 0.69)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **85.5**   **0.76 (0.68-- 0.83)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **95.4**   **0.72 (0.66-- 0.79)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **95.7**   **0.69 (0.59-- 0.81)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **80.8**
  **Ethnicity**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Asian                3     **0.72 (0.66-- 0.79)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **95.7**                               **0.48 (0.39-- 0.60)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **86.4**   **0.71 (0.63-- 0.80)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **96.4**   **0.68 (0.61-- 0.76)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **96.6**   **0.60 (0.49-- 0.75)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **84.2**
  Type of cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Prostate cancer      2     **0.75 (0.70-- 0.81)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **97.2**                               **0.56 (0.47-- 0.67)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **90.7**   **0.73 (0.66-- 0.82)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **97.6**   **0.69 (0.63-- 0.77)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}   **97.8**   **0.68 (0.58-- 0.80)**   **0.000**[^1^](#T3TFN1){ref-type="table-fn"}       **81.6**

The results are in bold if *P*\<0.05.

*P* was calculated by random model.

### One SNP in MALAT1 {#sec3-2-2}

The meta-analysis showed that MALAT1 rs619586 A/G polymorphism was associated with overall cancer risk. For the rs619586 A/G polymorphism, the allelic model, the heterozygote type AG and the dominant model were associated with decreased overall risk of cancer compared with the wild-type AA (G compared with A: *P*=0.003, OR = 0.77, 95% CI = 0.65--0.92; AG compared with AA: *P*=0.009, OR = 0.78, 95% CI = 0.65--0.94; dominant model: *P*=0.004, OR = 0.77, 95% CI = 0.64--0.92, [Table 3](#T3){ref-type="table"}).

### One SNP in HOTTIP {#sec3-2-3}

Our results suggested that the HOTTIP rs1859168 A/C polymorphism was associated with increased overall risk of cancer in all genetic models (C compared with A: *P*=0.000, OR = 1.32, 95% CI = 1.19--1.45; CC compared with AA: *P*=0.000, OR = 1.54, 95% CI = 1.27--1.87; AC compared with AA: *P*=0.006, OR = 1.24, 95% CI = 1.06--1.45; dominant model: *P*= 0.000, OR = 1.37, 95% CI = 1.19--1.59; recessive model: *P*=0.000, OR = 1.49, 95% CI = 1.26--1.76, [Table 3](#T3){ref-type="table"}).

### One SNP in HULC {#sec3-2-4}

In the present study, the allelic model, the heterozygote type AC, and the dominant model of HULC rs7763881 A/C polymorphism were associated with decreased overall risk of cancer compared with the wild-type AA (C compared with A: *P*=0.040, OR = 0.91, 95% CI = 0.83--0.99; AC compared with AA: *P*=0.000, OR = 0.74, 95% CI = 0.63--0.86; dominant model: *P*=0.000, OR = 0.77, 95% CI = 0.66--0.89, [Table 3](#T3){ref-type="table"}).

### Five SNPs in PRNCR1 {#sec3-2-5}

The pooled OR and stratified analyses showed that amongst the five PRNCR1 SNPs included in the meta-analysis, only rs16901946 G/A, rs13252298 G/A, rs1016343 T/C, and rs1456315 G/A were associated with cancer risk, while the association of the rs7007694 C/T was not statistically significant (*P*\>0.05).

The rs16901946 G/A polymorphism was associated with increased overall risk of cancer in all genetic models (A compared with G: *P*=0.001, OR = 1.15, 95% CI = 1.06--1.25; AA compared with GG: *P*=0.008, OR = 1.26, 95% CI = 1.06--1.50; AG compared with GG: *P*=0.017, OR = 1.15, 95% CI = 1.03--1.28; dominant model: *P*=0.003, OR = 1.17, 95% CI = 1.06--1.30; recessive model: *P*=0.019, OR = 1.21, 95% CI = 1.03--1.43).

For the rs13252298 G/A polymorphism, the allelic model, the mutation type AA, the heterozygote type AG, and the dominant model were associated with decreased overall risk of cancer compared with the wild-type GG (A compared with G: *P*=0.000, OR = 0.78, 95% CI = 0.72--0.85; AA compared with GG: *P*=0.000, OR = 0.68, 95% CI = 0.56--0.81; AG compared with GG: *P*=0.000, OR = 0.69, 95% CI = 0.62--0.77; dominant model: *P*=0.000, OR = 0.81, 95% CI = 0.73--0.90).

Additionally, the rs1016343 T/C polymorphism was associated with increased overall risk of cancer in all genetic models (C compared with T: *P*=0.000, OR = 1.31, 95% CI = 1.22--1.41; CC compared with TT: *P*=0.000, OR = 1.67, 95% CI = 1.41--1.97; CT compared with TT: *P*=0.000, OR = 1.35, 95% CI = 1.22--1.49; dominant model: *P*=0.000, OR = 1.41, 95% CI = 1.28--1.55; recessive model: *P*=0.000, OR = 1.42, 95% CI = 1.21--1.66).

The rs1456315 G/A polymorphism was associated with decreased overall risk of cancer in all genetic models (A compared with G: *P*=0.000, OR = 0.77, 95% CI = 0.72--0.83; AA compared with GG: *P*=0.000, OR = 0.59, 95% CI = 0.49--0.69; AG compared with GG: *P*=0.000, OR = 0.76, 95% CI = 0.68--0.83; dominant model: *P*=0.000, OR = 0.72, 95% CI = 0.66--0.79; recessive model: *P*=0.000, OR = 0.69, 95% CI = 0.59--0.81, [Table 3](#T3){ref-type="table"}).

Due to heterogeneity, we performed stratified analyses based on ethnicity and cancer type. Stratified analyses based on cancer type showed a significant association between the rs16901946 G/A polymorphism and increased risk of gastric cancer in the heterozygote type AG and the dominant model. In the Asian subgroup, the rs1016343 T/C polymorphism was associated with increased cancer risk in all genetic models. When stratified with cancer type, a significant association between the rs1456315 G/A polymorphism and decreased risk of prostate cancer was observed in our study ([Table 3](#T3){ref-type="table"}).

Heterogeneity {#sec3-3}
-------------

There was interstudy heterogeneity (slight, moderate, or severe) in the overall comparison and the subgroup analyses ([Table 3](#T3){ref-type="table"}). We subsequently performed sensitivity analyses to explore the influence of an individual study on the pooled results by estimating the sensitivity before and after the removal of the study from the analysis. Some ORs and 95% CIs ranged from insignificantly to statistically significant after individual studies were removed (Supplementary Table S2).

Publication bias {#sec3-4}
----------------

We used Begg's test and Egger's test to evaluate potential publication bias of the included studies. No statistically significant publication bias was indicated in any of the genetic models for all lncRNA SNPs ([Table 4](#T4){ref-type="table"}).

###### The results of Begg's and Egger's test for the publication bias

  Comparison type                               Begg's test           Egger's test   
  --------------------------------------------- ------------- ------- -------------- -------
  **ANRIL rs1333048 (A/C)**                                                          
  Allelic model                                 0.00          1.000   NA             NA
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          0.00          1.000   NA             NA
  Dominant model                                0.00          1.000   NA             NA
  Recessive model                               0.00          1.000   NA             NA
  **ANRIL rs4977574 (A/G)**                                                          
  Allelic model                                 0.00          1.000   NA             NA
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          0.00          1.000   NA             NA
  Dominant model                                0.00          1.000   NA             NA
  Recessive model                               0.00          1.000   NA             NA
  **ANRIL rs10757278 (A/G)**                                                         
  Allelic model                                 0.00          1.000   NA             NA
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          0.00          1.000   NA             NA
  Dominant model                                0.00          1.000   NA             NA
  Recessive model                               0.00          1.000   NA             NA
  **ANRIL rs1333045 (C/T)**                                                          
  Allelic model                                 0.00          1.000   NA             NA
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          0.00          1.000   NA             NA
  Dominant model                                0.00          1.000   NA             NA
  Recessive model                               0.00          1.000   NA             NA
  **MALAT1 rs619586 (A/G)**                                                          
  Allelic model                                 0.00          1.000   NA             NA
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          0.00          1.000   NA             NA
  Dominant model                                0.00          1.000   NA             NA
  Recessive model                               0.00          1.000   NA             NA
  **HOTTIP rs1859168 (A/C)**                                                         
  Allelic model                                 0.00          1.000   −0.86          0.548
  Mutation homozygote compared with wild-type   0.00          1.000   −0.46          0.725
  Heterozygote compared with wild-type          0.00          1.000   −1.02          0.494
  Dominant model                                0.00          1.000   −0.91          0.531
  Recessive model                               0.00          1.000   −0.75          0.590
  **HULC rs7763881 (A/C)**                                                           
  Allelic model                                 1.04          0.296   −3.13          0.197
  Mutation homozygote compared with wild-type   0.00          1.000   NA             NA
  Heterozygote compared with wild-type          1.04          0.296   −9.06          0.070
  Dominant model                                1.04          0.296   −5.60          0.113
  Recessive model                               0.00          1.000   NA             NA
  **PRNCR1 rs16901946 (G/A)**                                                        
  Allelic model                                 0.34          0.734   −0.71          0.553
  Mutation homozygote compared with wild-type   0.34          0.734   −0.71          0.553
  Heterozygote compared with wild-type          −0.34         1.000   0.38           0.742
  Dominant model                                −0.34         1.000   −0.27          0.810
  Recessive model                               0.34          0.734   −0.19          0.867
  **PRNCR1 rs13252298 (G/A)**                                                        
  Allelic model                                 1.22          0.221   3.30           0.046
  Mutation homozygote compared with wild-type   1.71          0.086   3.34           0.044
  Heterozygote compared with wild-type          0.24          0.806   1.07           0.363
  Dominant model                                0.73          0.462   0.70           0.535
  Recessive model                               1.71          0.086   1.82           0.166
  **PRNCR1 rs7007694 (C/T)**                                                         
  Allelic model                                 0.73          0.462   −1.42          0.251
  Mutation homozygote compared with wild-type   −0.34         1.000   −0.10          0.933
  Heterozygote compared with wild-type          1.71          0.086   −1.96          0.145
  Dominant model                                1.22          0.221   −1.70          0.188
  Recessive model                               −0.34         1.000   −0.04          0.974
  **PRNCR1 rs1016343 (T/C)**                                                         
  Allelic model                                 0.24          0.806   −0.87          0.450
  Mutation homozygote compared with wild-type   0.24          0.806   −0.83          0.467
  Heterozygote compared with wild-type          −0.24         1.000   0.25           0.820
  Dominant model                                −0.24         1.000   −0.15          0.888
  Recessive model                               0.73          0.462   −1.29          0.288
  **PRNCR1 rs1456315 (G/A)**                                                         
  Allelic model                                 1.22          0.221   1.74           0.181
  Mutation homozygote compared with wild-type   −0.24         1.000   0.27           0.810
  Heterozygote compared with wild-type          1.71          0.086   2.07           0.130
  Dominant model                                1.71          0.086   2.10           0.127
  Recessive model                               −0.24         1.000   0.20           0.862

Abbreviation: NA, not available.

Discussion {#sec4}
==========

It is known to all that over 20 lncRNA polymorphisms are associated with susceptibility of cancer. In recent studies, most of meta-analyses were conducted to focus on the association between lncRNA HOTAIR \[[@B27],[@B28]\] or lncRNA ZNRD1-AS1 \[[@B28]\] or lncRNA POLR2E \[[@B29]\] or lncRNA H19 \[[@B28],[@B30]\] polymorphisms and cancer risk. For example, the study of Lv et al. \[[@B28]\] included only four common lncRNA genes such as *H19, HOTAIR, ZNRD1-AS1*, and *PRNCR1*. However, more lncRNA polymorphisms with larger sample sizes are warranted. Therefore, a total of 12 SNPs in five common lncRNA genes were finally included in our study. In addition, our study was the first meta-analysis to show the significant association between the lncRNA ANRIL, MALAT1, HOTTIP, and HULC polymorphisms and cancer risk. Compared with the studies of Lv et al. \[[@B28]\] and Chu et al. \[[@B29]\], we decided to include more eligible studies related to lncRNA PRNCR1 genes according to the inclusion and exclusion criteria. Therefore, we included a larger size of cancer patients with more SNPs of lncRNA PRNCR1 into our study to confirm the results. More importantly, discussions about underlying mechanisms of each gene and the related polymorphisms were included in our study. It might help readers better understand the function of different lncRNA genes in cancer. Our study provides theoretical bases and research clues for future studies.

The ANRIL SNPs {#sec4-1}
--------------

Chromosome region 9p21 is a hotspot for disease-associated polymorphisms and encodes three tumor suppressors, namely p16^INK4a^, p14^ARF^, and p15^INK4b^, and the lncRNA ANRIL \[[@B31]\]. ANRIL is 3.8-kb long and expressed on the reverse strand. It has been shown to bind to and recruit polycomb repression complex 2 (PRC2) to repress the expression of p15^INK4B^ \[[@B32]\]. Further study showed that SNPs can disrupt ANRIL splicing and result in a circular transcript that is resistant to RNase digestion \[[@B7]\]. The circularized transcripts affect the normal function of ANRIL and INK4/ARF expression. For example, rs1333048 has been shown to be associated with the level of highly sensitive C-reactive protein (hsCRP), which is a biomarker for systemic inflammation \[[@B33]\] and breast cancer susceptibility \[[@B34]\]. And previous results have revealed that rs4977574 is significantly associated with the risk of coronary artery disease \[[@B35]\]. Moreover, rs10757278 has been reported to increase the ANRIL variant EU741058 expression which contains exons 1--5 of the long transcript \[[@B36]\]. In addition, this SNP might modulate the ANRIL binding site for the transcription factor STAT1, which in turn regulates ANRIL expression \[[@B37]\]. In conclusion, three SNPs in ANRIL (rs1333048 A/C, rs4977574 A/G, and rs10757278 A/G) can be used to determine cancer risk.

The MALAT1 SNPs {#sec4-2}
---------------

MALAT1 is located in chromosome 11q13, which is over 8000 nts long. It is enriched in nuclear speckles in interphase cells and concentrates in mitotic interchromatin granule clusters. And it is co-localized with pre-mRNA-splicing factor SF2/ASF and CC3 antigen in the nuclear speckles \[[@B38]\]. It is reported that lncRNA MALAT1 could regulate the expression through modulating transcription and the processing of post-transcriptional pre-mRNA in various genes \[[@B39]\]. Zhuo et al. \[[@B40]\] suggested that rs619586 SNP could bind with *miR-214* directly and suppress the expression of MALAT1. Several studies revealed that MALAT1 has an elevated expression and was associated with a higher risk and poorer survival in many kinds of cancers \[[@B41]\]. Our study showed that MALAT1 rs619586 A/G polymorphism was potential predictive biomarker of overall cancer risk.

The HOTTIP SNPs {#sec4-3}
---------------

HOTTIP is an antisense non-coding transcript located at the 5′-end of the *HOXA* gene cluster. The previous study showed that rs1859168 might change the expression level of HOTTIP by affecting transcription factor binding sites \[[@B17]\]. Furthermore, RNAfold web server also revealed that rs1859168 could alter the centroid secondary structure and minimum free energy. It might also influence the folding of HOTTIP and its function \[[@B17]\]. Further studies are warranted to explore the specific mechanisms. Our results suggested that the HOTTIP rs1859168 A/C polymorphism was associated with increased overall risk of cancer. Although the detailed mechanisms underlying the association of SNP in HOTTIP with cancer susceptibility are unclear, these findings could provide a new insight into understanding the genetic factors of cancer susceptibility and carcinogenesis.

The HULC SNPs {#sec4-4}
-------------

The lncRNA HULC is approximately 1.6 k nucleotide long and contains two exons but not translated \[[@B42]\]. Some studies have reported that HULC is highly up-regulated in hepatocellular carcinoma (HCC) and colorectal cancer (CRC) that metastasized to livers \[[@B42],[@B43]\]. Rs7763881 SNP changing from A to C in *HULC* gene was located in the 6p24.3 region. Based on the Hapmap database, all the SNPs in HULC are in high linkage disequilibrium (LD). For example, rs7763881 was in complete LD with rs1328867 (r^2^ = 1), which is located in the promoter region of HULC. Additionally, the wild-type allele T of rs1328867 is predicted to bind with some transcription factors including C-Myc \[[@B15]\]. It has been identified that C-Myc is critical in the regulation of the growth, differentiation, and apoptosis of both normal and neoplastic liver cells \[[@B44]\]. In conclusion, HULC rs7763881 A/C polymorphism was associated with decreased overall risk of cancer.

The PRNCR1 SNPs {#sec4-5}
---------------

The lncRNA PRNCR1, also referred to as PCAT8 and CARLo3, is transcribed from the 'gene desert' region of chromosome 8q24 (128.14--128.28 Mb) \[[@B24]\]. It has been stated that PRNCR1 is involved in the development of prostate cancer by activating androgen receptor (AR) \[[@B45]\]. Moreover, lncRNA PRNCR1 SNPs were observed to be risk of diverse cancers \[[@B21]\]. It might affect the predicted secondary structure of *PRNCR1* mRNA, altering the stability of PRNCR1 or the mRNA conformation, and giving rise to the modification of its interacting partners \[[@B24]\]. All the PRNCR1 polymorphisms in the exon region might result in the mechanism \[[@B28]\]. More specific mechanisms are warranted to be explored in further studies. Amongst the five PRNCR1 SNPs included in our study, rs16901946 G/A, rs13252298 G/A, rs1016343 T/C, and rs1456315 G/A could be predictive biomarkers of cancer risk.

Limitations {#sec5}
===========

Although this meta-analysis revealed the significant association between lncRNA polymorphisms and cancer risk, however, some limitations still should be acknowledged. First, the number of subjects in the included studies is relatively small, which might result in a lack of statistical power and prevent a meaningful analysis of the results. Second, in stratified analyses based on ethnicity and cancer type, we failed to perform further subgroup analysis because of limited relevant reports. Third, only English articles were included in our study and it may result in publication bias. Finally, study of the association between lncRNA polymorphisms and cancer risk remains an emerging field, we concluded only representative SNPs in our study. Therefore, additional prospective studies with larger sample sizes including other polymorphisms are warranted.

Summary and future directions {#sec6}
=============================

We systematically reviewed studies on the association between lncRNA SNPs and overall cancer risk, and used the available data to perform a meta-analysis of 19 SNPs in five common lncRNA genes. The results suggest that the association between lncRNA SNPs and cancer risk can be categorized into four types: (i) complete association, where polymorphisms are significantly associated with risk of overall cancer in all genetic models, including ANRIL rs1333048, HOTTIP rs1859168, PRNCR1 rs16901946, PRNCR1 rs1016343, and PRNCR1 rs1456315; (ii) ANRIL rs4977574, ANRIL rs10757278, MALAT1 rs619586, HULC rs7763881, and PRNCR1 rs13252298 polymorphisms are only associated with cancer risk in some genetic models; (iii) no association, where the association of polymorphisms with cancer risk are not statistically significant, including ANRIL rs1333045 and PRNCR1 rs7007694; (iv) failed to be quantitatively synthesized due to limited studies. Therefore, the lncRNA SNPs provide more alternatives for biomarkers that can predict cancer risk.

More attention should be paid to several research directions in the future studies. First, more lncRNA polymorphisms and other aspects of cancer including chemotherapeutic susceptibility, metastasis, and relapse should be explored. Second, functional studies are needed to clarify the underlying mechanisms of lncRNA polymorphism in the tumorigenesis. Finally, the extensive clinical application of lncRNA polymorphisms requires further study.
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ANRIL

:   antisense non-coding RNA in the INK4 locus

CRS

:   created restriction site

HOTTIP

:   HOXA distal transcript antisense RNA

HULC

:   highly up-regulated in liver cancer

HWE

:   Hardy--Weinberg equilibrium

LD

:   linkage disequilibrium

lncRNA

:   long non-coding RNA

MALAT1

:   metastasis-associated lung adenocarcinoma transcript 1

ncRNA

:   non-coding RNA

NOS

:   Newcastle--Ottawa scale

OR

:   odds ratio

PRNCR1

:   prostate cancer-associated non-coding RNA 1

RFLP

:   restriction fragment length polymorphism

SNP

:   single-nucleotide polymorphism

T-ARMS

:   tetra-primer amplification refractory mutation system

95% CI

:   95% confidence interval
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